Skip to main content
OpenTrials
Completed

NCT Number: NCT06537375

Use of Ketamine in Severe Pain Syndromes

Ketamine has been shown to have a certain efficiency in chronic pain syndromes. However, it is still not clearly known what is its efficiency and how ketamine is used in real world patients. In this retrospective study, all patients treated with ketamine for chronic pain in our hospital will be reviewed. Patients demographics, pain syndromes as well as outcome criteria will be collected to describe the use of ketamine in pain syndromes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain, Intractable Chronic Pain Mental Disorders Neurologic Manifestations Pain Pain Measurement Pain Syndrome Pain, Chronic Pathological Conditions, Signs and Symptoms Signs and Symptoms Somatoform Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Universitaire de Bruxelles - Hôpital erasme

Brussels, 1070, Belgium

About this study

The American Society of Regional Anesthesia and Pain Medicine, together with the American Academy of Pain and the American Society of Anesthesiologists published a consensus guideline in 2018 on the use of ketamine in chronic pain. A review of medical charts of all patients who received ketamine for chronic pain between january 2010 and june 2024 will be done. Demographic data, detailed pain scores, as well as description of the type of pain will be collected. Ketamine usage will be recorded for the dosage, as well as duration of the treatment. Outcome will be measured by before/after pain scores for neuropathic pain, as well as on a visual analog scale. A more global score (good-medium-no effect) will also be collected to get the patient's impression on their treatment. Concomitant pain medication will be collected.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients who received ketamine as treatment for a pain syndrome during january 2010 until june 2024 at Erasme University Hospital

Exclusion criteria

  • Age < 18 years
  • Patients who expressed their opposition to the use of their medical data
  • incomplete medical chart

Treatment and study plan

Primary outcomes

  1. Patient satisfaction

    Time frame: 6 month

    A scale (good-medium-no effect) of the efficacity of ketamine on their pain syndrome

  2. DN4

    Time frame: 6 month

    Neuropathic pain scale 4

  3. VAS

    Time frame: 6 month

    Visual analog scale of the pain intensity

Secondary outcomes

  1. Concomitant pain medications

    Time frame: 6 month

    Number of concomitant pain medications used by the patient

Sponsors and collaborators

Lead sponsor

Erasme University Hospital

Other

Registry information

Official study title

Use of Intravenous Ketamine in Patients with Severe Chronic Pain Syndromes

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Aug 5, 2024
Registry last updated
Feb 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.